FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS

Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be preferably delivered by gene therapy methods, particularly as a recombinant adeno-associated virus (rAAV) vector to the appropriate tissue.Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are 'biobetters' as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody. 提供了用于递送完全人源翻译后修饰的治疗性单克隆抗体及其抗原结合片段的方法和组合物。所述完全人源翻译后修饰的治疗性单克隆抗体可以优选通过基因治疗方法，特别是作为重组腺伴随病毒(rAAV)载体被递送至适当组织。还提供了制备AAV载体的方法、药物组合物和治疗方法。另外，提供了制备治疗性抗体的方法，所述治疗性抗体因为是完全人源翻译后修饰的而是"生物改进药"。这些完全人源翻译后修饰的治疗性抗体可以施用于需要该治疗性抗体治疗的受试者。